Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan PK and GST Polymorphism in HSCT Adults
NCT01071486Phase 4Withdrawn
- Sponsor
- Rambam Health Care Campus
- Start
- Aug 2009
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of busulfan in hematological malignancy and Benign Hematologic Disorder, sponsored by Rambam Health Care Campus. Primary endpoints: Hepatic Veno-Occlusive Disease at 24 weeks and Graft versus host disease at 24 weeks. Planned start Aug 2009; status: withdrawn.
02
Drugs
busulfan
03
Conditions
hematological malignancyBenign Hematologic Disorder
Beyond the preview
Go deeper on NCT01071486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01071486.